The genetic analysis of ovarian cancer.
作者信息
Shelling A N, Cooke I E, Ganesan T S
机构信息
ICRF Molecular Oncology Laboratory, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK.
出版信息
Br J Cancer. 1995 Sep;72(3):521-7. doi: 10.1038/bjc.1995.367.
Abstract
摘要
相似文献
1
The genetic analysis of ovarian cancer.卵巢癌的基因分析
Br J Cancer. 1995 Sep;72(3):521-7. doi: 10.1038/bjc.1995.367.
2
The search for the familial breast/ovarian cancer gene.
Trends Genet. 1993 Jan;9(1):22-6. doi: 10.1016/0168-9525(93)90068-S.
3
Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.卵巢癌中5号染色体长臂杂合性缺失常伴有TP53突变，并确定了5q13.1-21处的一个肿瘤抑制基因位点。
Br J Cancer. 1996 Jul;74(1):115-9. doi: 10.1038/bjc.1996.324.
4
5
6
7
Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.卵巢癌在染色体12p12.3 - 13.1（TEL和Kip1基因座区域）以及染色体12q23 - 末端经常出现杂合性缺失：这为两个新的肿瘤抑制基因提供了证据。
Br J Cancer. 1997;75(9):1256-62. doi: 10.1038/bjc.1997.214.
8
Human epithelial ovarian cancer allelotype.人类上皮性卵巢癌等位基因型
Cancer Res. 1993 May 15;53(10 Suppl):2393-8.
9
[Allelic losses of tumor suppressor gene on chromosome 17 in ovarian cancer].卵巢癌中17号染色体上肿瘤抑制基因的等位基因缺失
Nihon Sanka Fujinka Gakkai Zasshi. 1993 May;45(5):457-63.
10
Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12.卵巢癌中22号染色体杂合性缺失位于22q12处NF2基因的远端，且不伴有该基因的突变。
Br J Cancer. 1994 Nov;70(5):905-7. doi: 10.1038/bjc.1994.418.
引用本文的文献
1
Characterization of RNF144B and PPP2R2A identified by a novel approach using TCGA data in ovarian cancer.通过使用TCGA数据的新方法鉴定出的RNF144B和PPP2R2A在卵巢癌中的特征分析。
Sci Rep. 2025 Feb 13;15(1):5414. doi: 10.1038/s41598-024-76801-3.
2
Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.卵巢癌发生中遗传背景的复杂性——遗传不稳定性及其临床意义。
Cells. 2024 Feb 15;13(4):345. doi: 10.3390/cells13040345.
3
The Unique Biology behind the Early Onset of Breast Cancer.乳腺癌早期发病的独特生物学机制。
Genes (Basel). 2021 Mar 5;12(3):372. doi: 10.3390/genes12030372.
4
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.利用 MEK 抑制剂介导的 ERα 激活进行 ER 阳性卵巢癌的治疗干预。
PLoS One. 2013;8(2):e54103. doi: 10.1371/journal.pone.0054103. Epub 2013 Feb 4.
5
Genomic aberrations in borderline ovarian tumors.交界性卵巢肿瘤的基因组异常。
J Transl Med. 2010 Feb 26;8:21. doi: 10.1186/1479-5876-8-21.
6
The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.p53 作为卵巢癌化疗反应替代标志物的作用。
J Cancer Res Clin Oncol. 2010 Jan;136(1):79-88. doi: 10.1007/s00432-009-0639-8.
7
Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop.在卵巢癌细胞中，化疗药物的反应严格依赖于组织蛋白酶 D-Bax 激活环。
J Cell Mol Med. 2009 Jun;13(6):1096-109. doi: 10.1111/j.1582-4934.2008.00435.x. Epub 2008 Jul 24.
8
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.卵巢癌的早期检测与治疗：基于一种新的致癌模型，从早期阶段向疾病最小体积的转变。
Am J Obstet Gynecol. 2008 Apr;198(4):351-6. doi: 10.1016/j.ajog.2008.01.005.
9
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.卵巢癌的发病机制：形态学和分子生物学的启示及其临床意义
Int J Gynecol Pathol. 2008 Apr;27(2):151-60. doi: 10.1097/PGP.0b013e318161e4f5.
10
Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma.趋化因子（C-C基序）配体-2（CCL2）在卵巢腺癌中的表达降低。
Br J Cancer. 2005 Jun 6;92(11):2024-31. doi: 10.1038/sj.bjc.6602596.
本文引用的文献
1
Conclusions and recommendations from the Helene Harris Memorial Trust Fourth Biennial International Forum on Ovarian Cancer 11-14 May 1993, Toronto, Canada.1993年5月11日至14日于加拿大多伦多举行的海伦·哈里斯纪念信托基金第四届卵巢癌两年一度国际论坛的结论与建议。
Int J Gynecol Cancer. 1994 Mar;4(2):135-143. doi: 10.1046/j.1525-1438.1994.04020135.x.
2
Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer.卵巢癌中3号染色体短臂、6号染色体长臂、11号染色体短臂、17号染色体短臂和17号染色体长臂上特定基因座杂合性缺失的研究。
Int J Gynecol Cancer. 1993 Sep;3(5):293-298. doi: 10.1046/j.1525-1438.1993.03050293.x.
3
p53 gene mutations and protein accumulation in human ovarian cancer.人类卵巢癌中的p53基因突变与蛋白积累
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5. doi: 10.1073/pnas.90.11.4961.
4
Human epithelial ovarian cancer allelotype.人类上皮性卵巢癌等位基因型
Cancer Res. 1993 May 15;53(10 Suppl):2393-8.
5
p53 mutation is a common genetic event in ovarian carcinoma.p53基因变异是卵巢癌中常见的基因事件。
Cancer Res. 1993 May 1;53(9):2128-32.
6
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.早期上皮性卵巢癌中p53的突变与过表达
Obstet Gynecol. 1993 May;81(5 ( Pt 1)):643-50.
7
The search for the familial breast/ovarian cancer gene.
Trends Genet. 1993 Jan;9(1):22-6. doi: 10.1016/0168-9525(93)90068-S.
8
Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants.111例卵巢癌患者的细胞遗传学研究结果：治疗相关的染色体畸变和异染色质变异
Cancer Genet Cytogenet. 1993 Jan;65(1):35-46. doi: 10.1016/0165-4608(93)90056-r.
9
Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas.人类浆液性卵巢癌单灶起源的分子遗传学证据。
Gynecol Oncol. 1993 Jan;48(1):5-10. doi: 10.1006/gyno.1993.1002.
10
High incidence of mutations of the p53 gene detected in ovarian tumours by the use of chemical mismatch cleavage.通过化学错配切割在卵巢肿瘤中检测到p53基因突变的高发生率。
Cancer Lett. 1993 Jan 15;68(1):83-9. doi: 10.1016/0304-3835(93)90223-v.
Zotero 插件